OSL’s Pancreatic Cancer Treatment Approved for Sale in Europe
May 5, 2020
May 5, 2020 |
10 min
OncoSil Medical (ASX:OSL) has received CE Mark approval to market and sell its breakthrough implantable radiotherapy treatment for pancreatic cancer in the EU and UK.
OncoSil™ receives CE Mark approval
Apr 1, 2020
Apr 1, 2020 |
2 min
OncoSil Medical Ltd (ASX: OSL) has received CE Marking approval from the British Standards Institute (BSI) for its OncoSil™ device.
OncoSil granted FDA Breakthrough Device Designation
Mar 18, 2020
Mar 18, 2020 |
3 min
OncoSil Medical Ltd’s (ASX: OSL) OncoSil™ device has reached a significant milestone, receiving Breakthrough Device Designation by the US FDA for the treatment of unresectable locally advanced pancreatic cancer.
OncoSil on verge of CE Mark approval
Feb 27, 2020
Feb 27, 2020 |
5 min
The coming 12 months is shaping up as a watershed stage in the history of Oncosil Medical Ltd (ASX:OSL) as it flags the finalisation of commercialisation plans for its OncoSil™ device ahead of CE marking early in 2020.
ASX MedTech Junior Displays Promise for Pancreatic Cancer Patients
Jan 30, 2020
Jan 30, 2020 |
13 min
OncoSil Medical (ASX: OSL) has developed a first-in-class, truly innovative device that treats unresectable locally advanced pancreatic cancer — that is, tumours that can’t be surgically removed.
